Resetting the Pharma Agenda for a Post-COVID-19 World
This industry-leading event brings together the world’s biggest pharma companies and other major organizations across the life sciences and health care value chain to discuss key trends and issues that will help prepare stakeholders for a new wave of disruption and innovation for thriving in a post-COVID world.
However, pharma companies will look to drive growth through digital partnerships across the value chain and by expansion of research areas such as cell and gene therapies amidst the post- pandemic economic slowdown.
As the industry looks to invest in a “new normal”, it is imperative to bring a fresh perspective on the critical issues impacting the pharma and biotech companies such as the pharma pricing and politics, the potential of real-world evidence, and the opportunities and challenges of unconventional partnerships and collaborations across the new healthcare landscape.
FT US Pharma and Biotech Summit brings together leaders from across the industry to discuss these trends and create a successful life sciences ecosystem for a post-COVID world.